文摘
摘要目的:调查随时间变化的疲劳程度和伴随的静息状态的修改(RS)功能连通性(FC)在单胺能的网络在45疲劳后多发性硬化(MS)患者不同的症状治疗。
背景:疲劳是常见的和禁用女士治疗疲劳症状依靠药物加强单胺能的突触传递,表明单胺能的网络异常疲劳发病机制中的作用。
设计/方法:医学患者被随机,盲目地分配到治疗fampridine (n = 15),金刚烷胺(n = 15)或安慰剂(n = 15),并进行了临床神经心理学和3 t RS fMRI基线(T0)和后4周(W4)的治疗。15匹配的健康对照组(HC)获得两次。多巴胺、去甲肾上腺素和serotonin-related RS FC派生了独立分量分析(ICA),限制宠物地图册多巴胺,去甲肾上腺素和5 -羟色胺转运蛋白,获得高碳钢的大脑。的变化修改疲劳影响量表(小额信贷机构)评分和monoaminergic-related RS FC进行评估。
结果:医学患者显示基线异常vsHC在所有三个网络,与降低monoamine-related RS FC在颞枕,孤立和小脑地区,和提高RS FC在额叶,顶叶和皮质下区域。W4,小额信贷机构分数降低在所有患者组,没有time-by-treatment交互。W4 fampridine和金刚烷胺的患者显示增加多巴胺——noradrenaline-related RS FC在岛叶皮质,以及增加serotonin-related RS FC楔前叶/后扣带皮层。金刚烷胺的患者也显示增加多巴胺——noradrenaline-related RS FC的前扣带皮层(ACC)。相反,安慰剂的病人大多显示增加noradrenaline-related RS FC楔前叶和中间扣带皮层。Fampridine和安慰剂组显示趋势显著RS FC修改之间的相关性和小额信贷机构的改进(r =−0.49−0.52, p = 0.07 - -0.08)。
结论:在所有组疲劳改善。伴随monoaminergic-related RS FC的修改被发现在孤立、ACC和顶叶区域fampridine和金刚烷胺MS患者,在内侧顶叶区域对安慰剂的病人。
披露:玛丽亚Assunta罗卡已收到个人薪酬在500 - 4999美元的范围在拜耳的演讲人,生原体,百时美施贵宝公司,Celgene公司,Genzyme,默克公司Serono,诺华,罗氏,Teva。制度的玛丽亚Assunta罗卡收到意大利卫生部的研究支持,加拿大社会和女士基金会Italiana Sclerosi Multipla。Paola Valsasina已收到个人薪酬在500 - 4999美元的范围服务扬声器ACCMED管理局。Lamanna博士没有披露。布鲁诺科伦坡没有披露。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在百时美施贵宝公司的演讲人。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在赛诺菲Genzyme的演讲人。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在诺华的演讲人。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在罗氏的演讲人。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在默克的演讲人。 Dr. Martinelli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis, Biogen, Sanofi Genzyme, TEVA and Merck. Dr. Martinelli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck . Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).
